Clinical Trials Browser

Sarcoma

NCT04149691 2024-02-07

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Phase 1 Unknown

42 enrolled

GastrointestinalGenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Carcinoma, Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04595994 2024-01-23

SeliSarc

Phase 1 Unknown

14 enrolled

Sarcoma

NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1 Unknown

50 enrolled

Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT03462316 2023-04-12

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Phase 1 Unknown

20 enrolled

Sarcoma

Bone Neoplasms, Sarcoma

NCT04318964 2023-04-12

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Basal Cell, Colonic Neoplasms, Lymphoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT05415098 2022-11-16

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Phase 1 Unknown

90 enrolled

GastrointestinalHead & NeckLymphoidOther solid neoplasmSarcomaThoracic

Nasopharyngeal Carcinoma, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Stomach Neoplasms, Lymphoma, B-Cell

NCT04556669 2021-05-27

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Phase 1 Unknown

30 enrolled

GynecologicSarcoma

Uterine Cervical Neoplasms, Sarcoma

NCT04659733 2020-12-09

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Phase 1 Unknown

36 enrolled

Sarcoma

NCT04107142 2019-09-27

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Phase 1 Unknown

10 enrolled

BreastGastrointestinalGenitourinaryHead & NeckSarcoma

Nasopharyngeal Carcinoma, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03002805 2019-08-19

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

Phase 1 Unknown

46 enrolled

Sarcoma

NCT03076372 2018-02-27

A Study Evaluating MM-310 in Patients With Solid Tumors

Phase 1 Unknown

34 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00101309 2013-12-18

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

Phase 1 Unknown

10 enrolled

CNSSarcoma

Neuroblastoma, Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Clinical Trials

DOXO75

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

SeliSarc

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

TAEST16001 in the Treatment of Soft Tissue Sarcoma

OLATRASTS

GEN602

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

A Study Evaluating MM-310 in Patients With Solid Tumors

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma